Dr Mehrdad Nikfarjam
MD, PhD, FRACS
Liver, Pancreatic and Biliary Surgeon
University of Melbourne
Clinical research: Advanced and minimally invasive pancreatic resection techniques. Borderline resectable pancreatic cancers. Neoadjuvant and adjuvant chemotherapy trials. Enhanced post -operative recovery techniques. Fluid sparing therapies in pancreatic surgery. Familial pancreatic cancer screening.
Basic Research: Mouse models of pancreatic cancer. K-ras targeted therapies. Role of P-21 Kinase in the development and progression of pancreatic cancer.
Dr Chris Scarlett
Head – Discipline of Applied Sciences
School of Environmental & Life Sciences
Head, Pancreatic Cancer Research
Nutrition, Food & Health Research Group
University of Newcastle
Research interests: Drug development for pancreatic cancer and mouse models of pancreatic cancer.
Dr Ilse Rooman
Head Pancreatic Tumourigenesis Group
The Garvan Institute of Medical Research,The Kinghorn Cancer Centre
Conjoint Senior Lecturer University New South Wales Australia
Conjoint Research Professor Vrije Universiteit Brussel
Research Interests: Cellular plasticity in the context of pancreatitis, regeneration and pancreatic cancer. Study of new genes and pathways that are aberrantly expressed in pancreas tumour development (hypothesis driven approach and unbiased integrative –omics analyses).
Dr John Chen
MBBS PhD FRACS
HepatoPancreatoBiliary and Liver Transplant Surgeon: Flinders Medical Centre and Royal Adelaide Hospital
Director of South Australian Liver Transplant Unit: Flinders Medical Centre
Research interests: Research in the areas of pancreatic, biliary and liver malignacies. Recent publications in the outcomes of pancreatic cancer resections, liver cancer treated with resections and liver ransplantation. ERCP interventions in pancreatobiliatry diseases. Doctorate thesis in pathobiology of acute pancreatitis especially with respect to sphincter of Oddi dysfunction and multiorgan failure predictive scoring system.
Dr Marina Pajic
Research Interests: Testing and validation of novel druggable targets and therapeutic regimens in early development for the treatment of pancreatic cancer. Development and characterisation of novel, robust preclinical models of pancreatic cancer as a platform for comprehensive pre-clinical screening. Discovery of prognostic biomarkers and clinically useful biomarker-guided treatment combinations for pancreatic cancer.
Prof Richard Turner
MBBS (Hons), BMedSc, FRACS, PhD
Professor of Surgery, University of Tasmania School of Medicine
Director, Hobart Clinical School
Consultant General Surgeon, Royal Hobart Hospital
Acute and chronic pancreatitis
Pancreatic exocrine insufficiency
Chronic disease management
(Medical education and assessment)
Dr Lorraine Chantrill
B.Sc. (Hons); M.B.B.S. (Hons); FRACP
Lorraine is completing her PhD in Andrew Biankin’s laboratory at The Kinghorn Cancer Centre and a Staff Specialist medical oncologist at the Macarthur Cancer Therapy Centre in Sydney’s South West. She is the Principal Investigator on several clinical trials, one of which is the IMPaCT study of biologically targeted treatment for metastatic pancreas cancer which is a truly collaborative, translational clinical trial within the Sydney Catalyst portfolio. She is chair of the Upper GI working party of the AGITG and a co-chair of the APC/AGITG pancreas cancer workshop.
Dr Rachel Neale
Head, Cancer Aetiology Group, QIMR Berghofer Medical Research Institute
Research interests: Genetic and environmental causes of pancreatic cancer. Patterns of care in patients with pancreatic cancer in Australia, including factors that influence the management of patients with pancreatic cancer and how variability in care influences outcomes including survival, length of stay in hospital and quality of life.
Immediate past president
Prof Ross Smith
MBBS MD FRACS
Head, Cancer Surgery and Metabolism Laboratory,
Started a pancreatico-biliary surgical group at Concord Hospital in 1979 with early interests in biliary drainage for jaundiced patients requiring surgery. Undertook a MD in surgical nutrition Leeds and followed by managing a intestinal failure practice as well as a busy pancreatico biliary practice at Royal North Shore hospital from 1983. The laboratory has concentrated on pancreatic cancer since 1978 with a large tissue bank and multiple laboratory techniques. The laboratory is developing novel therapies and biomarkers for pancreatic cancer.